Skip to main content
46°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
bluebird bio, Inc. - Common Stock
(NQ:
BLUE
)
3.900
-0.240 (-5.80%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about bluebird bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Is Bluebird Bio Stock a Buy?
April 15, 2024
This small biotech is struggling to fly -- and investors should probably steer clear.
Via
The Motley Fool
Better Buy: Bluebird Bio Vs. Novavax
April 13, 2024
Who wins this face-to-face between two beaten-down biotechs?
Via
The Motley Fool
Is This Beaten-Down Stock a Good Acquisition Target?
April 11, 2024
This company has proven its innovative abilities, but that's not enough to outperform the market.
Via
The Motley Fool
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
March 29, 2024
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.
Via
The Motley Fool
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
March 28, 2024
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia.
Via
Investor's Business Daily
Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
March 27, 2024
Via
Benzinga
Peering Into bluebird bio's Recent Short Interest
March 22, 2024
Via
Benzinga
Is Bluebird Bio Stock a Buy Now?
March 13, 2024
Are you feeling brave?
Via
The Motley Fool
Forecasting The Future: 6 Analyst Projections For bluebird bio
March 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 26, 2024
Via
Benzinga
Earnings Scheduled For March 26, 2024
March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
Via
Benzinga
Why Bluebird Bio Stock Flew Higher Than the Market Today
March 18, 2024
The company was thrown a financial lifeline.
Via
The Motley Fool
(BLUE) - Analyzing bluebird bio's Short Interest
February 29, 2024
Via
Benzinga
Why Bluebird Bio Stock Dived Into the Red on Tuesday
March 05, 2024
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation.
Via
The Motley Fool
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
Via
Benzinga
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
February 27, 2024
Both companies are working on treatments for genetic disorders.
Via
Investor's Business Daily
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
January 27, 2024
The answer hardly inspires confidence.
Via
The Motley Fool
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...
Via
Benzinga
Exposures
Product Safety
2 Red Flags for Bluebird Bio Stock
January 10, 2024
The biotech's struggles may continue.
Via
The Motley Fool
Better Risky Investment: Bluebird Bio vs. Shiba Inu
January 03, 2024
Few investors dare to tread where the ice is known to be very thin.
Via
The Motley Fool
Should You Invest in Bluebird Bio Right Now?
December 26, 2023
After two December share price crashes, there's no evident cure for Bluebird Bio's ills.
Via
The Motley Fool
If You Invested $10,000 in Bluebird Bio In 2021, This Is How Much You Would Have Today
December 24, 2023
Can things get better for this struggling stock?
Via
The Motley Fool
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
December 23, 2023
The stock has been in the news lately.
Via
The Motley Fool
3 Money-Saving Tricks for Investing in Biotech Stocks in 2024
December 22, 2023
Doing a little math and doing a little extra research can make a big difference.
Via
The Motley Fool
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
December 22, 2023
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.
Via
The Motley Fool
Exposures
Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 21, 2023
Via
Benzinga
S&P 500 Edges Lower; General Mills Cuts Sales Forecast
December 20, 2023
U.S. stocks traded mixed toward the end of trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.07% to 37,586.02 while the NASDAQ rose 0.17% to 15,029.36. The S&P 500, however,...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
December 20, 2023
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 20, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.